Oncology Expert Insights

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

December 19th 2024

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

ByMisako Nagasaka, MD, PhD

December 9th 2024

Dr Nagasaka discusses the use of T-DXd in patients with unresectable or metastatic HER2-positive NSCLC.

Binod Dhakal, MD, associate professor, medicine, Division of Hematology, Medical College of Wisconsin; Muhamed Baljevic, MD, associate professor, medicine, Division of Hematology Oncology, director, Plasma Cell Disorders Research, director, Vanderbilt Amyloidosis Multidisciplinary Program, co-chair, Protocol Review and Monitoring System, disease team lead, plasma cell dyscrasias and lymphomas, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

ByBinod Dhakal, MD,Muhamed Baljevic, MD

December 5th 2024

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

John Strickler, MD, professor, medicine, Division of Medical Oncology, associate director, Clinical Research – GI Oncology, co-leader, Precision Cancer Medicine and Investigational Therapeutics Program, Duke Cancer Institute

Pancreatic Cancer Research Reveals Treatment Developments and Challenges: With John Strickler, MD

ByJohn Strickler, MD

December 2nd 2024

Dr Strickler discusses the challenges of targeting RAS alterations in pancreatic cancer and efforts to improve pancreatic cancer screening rates.

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

ByAlexey V. Danilov, MD, PhD,Nicole Lamanna, MD

November 25th 2024

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, head, Division of Radiotherapy and Imaging, The Institute of Cancer Research; fellow, the Royal College of Physicians, the Royal College of Radiologists

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

ByKevin Harrington, MD, PhD, FRCP, FRCR, FRSB

November 18th 2024

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

Premal Thaker, MD, MS, David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, director, Gynecologic Oncology Clinical Research, interim chief, Division of Gynecologic Oncology, School of Medicine, Washington University in St. Louis, Siteman Cancer Center

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

ByPremal H. Thaker, MD, MS

November 11th 2024

Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.

Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, medical director, Thoracic Cancer Program, Associate Executive Director, AdventHealth Cancer Institute

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

ByTarek M. Mekhail, MD, MSc, FRCSI, FRCSEd

November 4th 2024

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Joleen Hubbard, MD, medical oncologist, Allina Health Cancer Institute

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

ByJoleen M. Hubbard, MD

October 31st 2024

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.

David R. Gandara, MD, chief medical officer, International Society of Liquid Biopsy; co-director, Center for Experimental Therapeutics in Cancer, senior advisor to the director, University of California Davis Comprehensive Cancer Center; adjunct clinical professor, Translational and Clinical Research Program, University of Hawaii Cancer Center

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

ByDavid R. Gandara, MD

October 28th 2024

Dr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

ByAaron Gerds, MD, MS,James K. McCloskey, MD

October 14th 2024

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

ByRory Shallis, MD

September 26th 2024

Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

ByNarjust Florez, MD

September 5th 2024

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

ByRavi Salgia, MD, PhD

September 2nd 2024

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Anne Chiang, MD, PhD, associate professor, medicine, Section of Medical Oncology, Yale School of Medicine; associate director, Clinical Initiatives, Yale Cancer Center

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

ByAnne Chiang, MD

August 29th 2024

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

ByKomal Jhaveri, MD, FACP

August 22nd 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

ByGuillermo Garcia-Manero, MD

August 19th 2024

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

ByJulia Rotow, MD

August 8th 2024

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Balazs Halmos, MD, MS, professor, Departments of Oncology and Medicine, Albert Einstein College of Medicine; associate director, Clinical Science, Montefiore Einstein Comprehensive Cancer Center

Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC

ByBalazs Halmos, MD

August 5th 2024

Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

ByAaron Lisberg, MD

August 1st 2024

Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.

Mark Pegram, MD, Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology, associate dean, Clinical Research Quality, Stanford University School of Medicine; associate director, Clinical Research, Stanford Comprehensive Cancer Institute; medical director, Stanford Clinical Translational Research Unit

Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer

ByMark D. Pegram, MD

July 29th 2024

Dr Pegram discusses the use of oral SERDs in HR-positive metastatic breast cancer and biomarker testing practices for patients with metastatic disease.

David Miller, MD, professor, chief, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Amy and Vernon R. Faulconer Distinguished Chair in Gynecologic Oncology, University of Texas (UT) Southwestern Medical School; medical director, UT Southwestern Harold C. Simmons Cancer Center

Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

ByDavid Miller, MD

July 25th 2024

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

ByNam Bui, MD,Ciara Kelly, MBBCh, BAO

July 18th 2024

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, European Institute of Oncology

Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

ByGiuseppe Curigliano, MD, PhD

July 15th 2024

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

ByRobert Z. Orlowski, MD, PhD

July 11th 2024

Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

ByMartin Dietrich, MD, PhD,Michelle Shiller, DO

June 27th 2024

Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.

Mark Agulnik, MD, professor, clinical medicine, vice chair, faculty development, Department of Medicine, section chief, Sarcomas & Melanoma, Keck School of Medicine, the University of Southern California

Agulnik Highlights Key Updates in GIST Research and Management

ByMark Agulnik, MD

June 24th 2024

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

ByKaren Reckamp, MD

June 20th 2024

Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.

Ari Rosenberg, MD, assistant professor, medicine, University of Chicago Medicine

Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma

ByAri Rosenberg, MD

June 17th 2024

Dr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center

Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations

ByPaul K. Paik, MD

June 6th 2024

Dr Paik discusses the VISION trial of tepotinib in NSCLC harboring MET exon 14 skipping alterations and real-world data from the TOGETHER pooled analysis.